Established prostate cancer susceptibility variants are not associated with disease outcome

Fredrik E. Wiklund, Hans Olov Adami, Sigun L. Zheng, Pär Stattin, William B Isaacs, Henrik Grönberg, Jianfeng Xu

Research output: Contribution to journalArticle

Abstract

Recent genome-wide association studies have been successful in identifying common sequence variants associated with prostate cancer risk; however, their importance in prostate cancer prognosis remains unknown. To assess confirmed prostate cancer susceptibility variants with prostate cancer prognosis, we genotyped 16 established susceptibility variants in a Swedish cohort of 2,875 prostate cancer cases, ascertained between 2001 and 2003, with complete follow-up regarding vital status through January 2008. Cox regression models, adjusted for age, clinical stage, pathologic grade, nodal or distant metastases, and diagnostic serum levels of prostate-specific antigen level, were used to assess association between risk variants and prostate cancer-specific survival. During follow-up, 626 men died, and of those, 440 had prostate cancer classified as their underlying cause of death. We found no association between any of the explored sequence variants and prostate cancer-specific mortality, either in exploring individual variants or in assessing the cumulative effect of all variants. We conclude that hitherto established prostate cancer susceptibility variants are not associated with the lethal potential of prostate cancer.

Original languageEnglish (US)
Pages (from-to)1659-1662
Number of pages4
JournalCancer Epidemiology Biomarkers and Prevention
Volume18
Issue number5
DOIs
StatePublished - May 2009

Fingerprint

Prostatic Neoplasms
Genome-Wide Association Study
Prostate-Specific Antigen
Proportional Hazards Models
Cause of Death
Neoplasm Metastasis
Survival
Mortality
Serum

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Established prostate cancer susceptibility variants are not associated with disease outcome. / Wiklund, Fredrik E.; Adami, Hans Olov; Zheng, Sigun L.; Stattin, Pär; Isaacs, William B; Grönberg, Henrik; Xu, Jianfeng.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 18, No. 5, 05.2009, p. 1659-1662.

Research output: Contribution to journalArticle

Wiklund, Fredrik E. ; Adami, Hans Olov ; Zheng, Sigun L. ; Stattin, Pär ; Isaacs, William B ; Grönberg, Henrik ; Xu, Jianfeng. / Established prostate cancer susceptibility variants are not associated with disease outcome. In: Cancer Epidemiology Biomarkers and Prevention. 2009 ; Vol. 18, No. 5. pp. 1659-1662.
@article{fee58332a0a7402cb58016a1c21a1ec4,
title = "Established prostate cancer susceptibility variants are not associated with disease outcome",
abstract = "Recent genome-wide association studies have been successful in identifying common sequence variants associated with prostate cancer risk; however, their importance in prostate cancer prognosis remains unknown. To assess confirmed prostate cancer susceptibility variants with prostate cancer prognosis, we genotyped 16 established susceptibility variants in a Swedish cohort of 2,875 prostate cancer cases, ascertained between 2001 and 2003, with complete follow-up regarding vital status through January 2008. Cox regression models, adjusted for age, clinical stage, pathologic grade, nodal or distant metastases, and diagnostic serum levels of prostate-specific antigen level, were used to assess association between risk variants and prostate cancer-specific survival. During follow-up, 626 men died, and of those, 440 had prostate cancer classified as their underlying cause of death. We found no association between any of the explored sequence variants and prostate cancer-specific mortality, either in exploring individual variants or in assessing the cumulative effect of all variants. We conclude that hitherto established prostate cancer susceptibility variants are not associated with the lethal potential of prostate cancer.",
author = "Wiklund, {Fredrik E.} and Adami, {Hans Olov} and Zheng, {Sigun L.} and P{\"a}r Stattin and Isaacs, {William B} and Henrik Gr{\"o}nberg and Jianfeng Xu",
year = "2009",
month = "5",
doi = "10.1158/1055-9965.EPI-08-1148",
language = "English (US)",
volume = "18",
pages = "1659--1662",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Established prostate cancer susceptibility variants are not associated with disease outcome

AU - Wiklund, Fredrik E.

AU - Adami, Hans Olov

AU - Zheng, Sigun L.

AU - Stattin, Pär

AU - Isaacs, William B

AU - Grönberg, Henrik

AU - Xu, Jianfeng

PY - 2009/5

Y1 - 2009/5

N2 - Recent genome-wide association studies have been successful in identifying common sequence variants associated with prostate cancer risk; however, their importance in prostate cancer prognosis remains unknown. To assess confirmed prostate cancer susceptibility variants with prostate cancer prognosis, we genotyped 16 established susceptibility variants in a Swedish cohort of 2,875 prostate cancer cases, ascertained between 2001 and 2003, with complete follow-up regarding vital status through January 2008. Cox regression models, adjusted for age, clinical stage, pathologic grade, nodal or distant metastases, and diagnostic serum levels of prostate-specific antigen level, were used to assess association between risk variants and prostate cancer-specific survival. During follow-up, 626 men died, and of those, 440 had prostate cancer classified as their underlying cause of death. We found no association between any of the explored sequence variants and prostate cancer-specific mortality, either in exploring individual variants or in assessing the cumulative effect of all variants. We conclude that hitherto established prostate cancer susceptibility variants are not associated with the lethal potential of prostate cancer.

AB - Recent genome-wide association studies have been successful in identifying common sequence variants associated with prostate cancer risk; however, their importance in prostate cancer prognosis remains unknown. To assess confirmed prostate cancer susceptibility variants with prostate cancer prognosis, we genotyped 16 established susceptibility variants in a Swedish cohort of 2,875 prostate cancer cases, ascertained between 2001 and 2003, with complete follow-up regarding vital status through January 2008. Cox regression models, adjusted for age, clinical stage, pathologic grade, nodal or distant metastases, and diagnostic serum levels of prostate-specific antigen level, were used to assess association between risk variants and prostate cancer-specific survival. During follow-up, 626 men died, and of those, 440 had prostate cancer classified as their underlying cause of death. We found no association between any of the explored sequence variants and prostate cancer-specific mortality, either in exploring individual variants or in assessing the cumulative effect of all variants. We conclude that hitherto established prostate cancer susceptibility variants are not associated with the lethal potential of prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=66549083321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66549083321&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-08-1148

DO - 10.1158/1055-9965.EPI-08-1148

M3 - Article

VL - 18

SP - 1659

EP - 1662

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 5

ER -